NEW YORK, April 7, 2008 Forest Laboratories,Inc. (NYSE: FRX), an international manufacturer and marketer of pharmaceuticalproducts, will release its Fiscal 2008 Fourth Quarter financial results beforethe U.S. stock market opens on Tuesday, April 15, 2008. Later that day, at10:00 AM EDT, Forest will host a conference call where Dr. Lawrence Olanoff,President and Chief Operating Officer and Frank Perier, Senior Vice Presidentand Chief Financial Officer, will discuss the financial results and relevantcompany and industry topics. The conference call will be webcast livebeginning at 10:00 AM EDT on the Company's website www.frx.com and also on thewebsite www.streetevents.com. Please log on to either website at least fifteenminutes prior to the conference call as it may be necessary to downloadsoftware to access the call. A replay of the conference call will beavailable until April 30, 2008 at both websites and also by dialing1-800-642-1687 (US investors) or +1-706-645-9291 (international investors), ID42636974.
(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )
About Forest Laboratories and Its Products
Forest Laboratories is a US-based pharmaceutical company dedicated toidentifying, developing, and delivering products that make a positivedifference in peoples' lives. Forest Laboratories' growing product lineincludes Lexapro(R) (escitalopram oxalate), an SSRI indicated foradults for the initial and maintenance treatment of major depressivedisorder and generalized anxiety disorder; Namenda(R) (memantine HCl), anN-methyl-D-aspartate (NMDA)-receptor antagonist indicated for the treatment ofmoderate to severe Alzheimer's disease; Campral(R)* (acamprosate calcium),indicated in combination with psychosocial support for the maintenance ofabstinence from alcohol in patients with alcohol dependence who are abstinentat treatment initiation, and Bystolic(TM) (nebivolol), a beta-adrenergicreceptor blocking agent indicated for the treatment of hypertension. Inaddition to our growing product line, Forest also co-promotes the DaiichiSankyo, Inc. product Azor(TM)* (amlodipine and olmesartan medoxomil), acalcium channel blocker and angiotensin receptor blocker combination productindicated for the treatment of hypertension. For more information, visitwww.frx.com.
Except for the historical information contained herein, this releasecontains forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. These statements involve a number ofrisks and uncertainties, including the difficulty of predicting FDA approvals,the acceptance and demand for new pharmaceutical products, the impact ofcompetitive products and pricing, the timely development and launch of newproducts, and the risk factors listed from time to time in the ForestLaboratories' Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, andany subsequent SEC filings.* Azor is a trademark of Daiichi Sankyo, Inc. and Campral is a registered trademark of Merck Sante s.a.s., a subsidiary of Merck KGaA, Darmstadt, Germany.
SOURCE Forest Laboratories, Inc.